Sugi Predict

Sugi Predict / Compounds / SCHEMBL2339978

SCHEMBL2339978

SCHEMBL2339978

COc1cc(Cl)nc(Cl)n1

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 5/20 0.47
▸ HTT P42858 1/20 0.47
▸ SMN1; SMN2 Q16637 4/20 0.43
▸ LMNA P02545 2/20 0.43
▸ KDM4E B2RXH2 3/20 0.42
▸ CYP1A2 P05177 1/20 0.39
▸ TDP1 Q9NUW8 1/20 0.38
▸ TAS1R3 Q7RTX0 1/20 0.38
▸ TAS1R1 Q7RTX1 1/20 0.38
▸ TAS1R2 Q8TE23 1/20 0.38
▸ HSP90AA1 P07900 1/20 0.37
▸ HSP90AB1 P08238 1/20 0.37
▸ L3MBTL1 Q9Y468 2/20 0.36
▸ PDE2A O00408 1/20 0.35
▸ POLB P06746 1/20 0.35
▸ NPC1 O15118 1/20 0.34
▸ RAB9A P51151 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL150750 0.87 ALDH1A1 (0.52) ALDH1A1HTTSMN1; SMN2LMNAKDM4E
SCHEMBL29228586 0.86 ALDH1A1 (0.62) ALDH1A1HTTSMN1; SMN2LMNAKDM4E
SCHEMBL4041048 0.81 ALDH1A1 (0.49) ALDH1A1SMN1; SMN2LMNAKDM4ECYP1A2
Trimethylammonium SCHEMBL9045332 0.81 ALDH1A1 (0.47) ALDH1A1HTTSMN1; SMN2LMNAKDM4E
SCHEMBL2131428 0.79 ALDH1A1 (0.70) ALDH1A1HTTSMN1; SMN2LMNAKDM4E
SCHEMBL10241852 0.79 PDE2A (0.52) ALDH1A1HTTSMN1; SMN2LMNAKDM4E
SCHEMBL105629 0.79 LMNA (0.55) ALDH1A1SMN1; SMN2LMNAKDM4ECYP1A2
SCHEMBL30318701 0.79 PDE2A (0.52) ALDH1A1HTTSMN1; SMN2LMNAKDM4E
SCHEMBL11834614 0.79 ALDH1A1 (0.46) ALDH1A1HTTSMN1; SMN2LMNAKDM4E
SCHEMBL29693683 0.79 LMNA (0.55) ALDH1A1SMN1; SMN2LMNAKDM4ECYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 231 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117062813-B Polycyclic compound and application thereof 四川汇宇制药股份有限公司 2026-05-19 — — CN disclosed
WO-2026101724-A1 AMINO PYRIMIDINE AND AMINO TRIAZINE ANALOGS FOR TREATING CANCER NEREID THERAPEUTICS INCORPORATED (US) 2026-05-15 — — WO disclosed
US-20250223280-A1 POTENT ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF IMMUNOGLOBULINS AND OTHER PROTEINS AVILAR THERAPEUTICS, INC. (US) 2025-07-10 — — US disclosed
US-12312340-B2 Potent ASGPR-binding compounds for the degradation of immunoglobulins and other proteins AVILAR THERAPEUTICS, INC. (US) 2025-05-27 — — US disclosed
WO-2025067239-A1 KINESIN KIF18A INHIBITOR, AND APPLICATION THEREOF 上海湃隆生物科技有限公司 2025-04-03 — — WO disclosed
EP-4524136-A1 KINESIN KIF18A INHIBITOR AND USE THEREOF Shanghai Apeiron Therapeutics Company Limited (CN) 2025-03-19 — — EP disclosed
US-20250084084-A1 Crystalline form of (2R)-2-(5-fluoro-2-methoxypyridin-4-yl)-1-[(2S)-7-methyl-6-(pyrimidin-2-yl)-3,4-dihydro-1H-spiro[1,8-naphthyridine-2,3-pyrrolidin]-1-yl]propan-1-one PFIZER INC. (US) 2025-03-13 — — US disclosed
WO-2025026392-A1 KINESIN KIF18A INHIBITOR AND USE THEREOF 上海湃隆生物科技有限公司 2025-02-06 — — WO disclosed
CN-119221135-A Method for preparing on-DNA aryl acetonitrile compound 正大天晴药业集团股份有限公司 2024-12-31 — — CN disclosed
CN-119156382-A Kinesin KIF18A inhibitor and application thereof 上海湃隆生物科技有限公司 2024-12-17 — — CN disclosed
US-5099019-A Central nervous system steroid derivative drugs UPJOHN COMPANY (US) 1992-03-24 — — US disclosed
EP-0446743-A2 Herbicidal sulfonylureas, process for their preparation and intermediates BASF Aktiengesellschaft (DE) 1991-09-18 — — EP disclosed
EP-0445642-A1 2-Amino-(fluoralkoxy-pyrimidines) and process for their preparation BASF Aktiengesellschaft (DE) 1991-09-11 — — EP disclosed
EP-0445644-A1 Trifluoro- respectively chlorodifluoromethoxy pyrimidines and process for their preparation BASF Aktiengesellschaft (DE) 1991-09-11 — — EP disclosed
US-4996318-A Amino-9,10-secosteroids useful for treating head injury, spinal cord trauma or stroke THE UPJOHN COMPANY (US) 1991-02-26 — — US disclosed
EP-0358676-A1 PHARMACEUTICALLY ACTIVE AMINES THE UPJOHN COMPANY (US) 1990-03-21 — — EP disclosed
EP-0354920-A1 AMINO-9,10-SECOSTEROIDS THE UPJOHN COMPANY (US) 1990-02-21 — — EP disclosed
EP-0293078-A1 Pharmaceutically active amines THE UPJOHN COMPANY (US) 1988-11-30 — — EP disclosed
WO-1988008424-A1 PHARMACEUTICALLY ACTIVE AMINES THE UPJOHN COMPANY (US) 1988-11-03 — — WO disclosed
WO-1988007527-A1 AMINO-9,10-SECOSTEROIDS THE UPJOHN COMPANY (US) 1988-10-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12312340-B2 Potent ASGPR-binding compounds for the degradation of immunoglobulins and other proteins ASGR1, FCGR2A, FCGR3B ALDH1A1 3256/4885HTT 4253/4885SMN1; SMN2 4367/4885
US-20250084084-A1 Crystalline form of (2R)-2-(5-fluoro-2-methoxypyridin-4-yl)-1-[(2S)-7-methyl-6-(pyrimidin-2-yl)-3,4-dihydro-1H-spiro[1,8-naphthyridine-2,3-pyrrolidin]-1-yl]propan-1-one CSPP1, PRNP, RPLP2 ALDH1A1 305/4885HTT 1284/4885SMN1; SMN2 1119/4885
US-20250223280-A1 POTENT ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF IMMUNOGLOBULINS AND OTHER PROTEINS ASGR1, FCGR2A, FCGR3B ALDH1A1 3256/4885HTT 4253/4885SMN1; SMN2 4367/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.